Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults

Next Previous
Trial Profile

A Phase Ib/II, Multicentre, Double-blind, Randomised, Placebo-controlled, Dose Escalation and Dose-finding Study to Evaluate the Safety and Efficacy of IPN10200 in Improving the Appearance of Moderate to Severe Upper Facial Lines in Adults

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum-Toxin-A (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Acronyms LANTIC
  • Sponsors Ipsen

Most Recent Events

  • 22 Sep 2025 Primary endpoint has been met (Response to treatment as measured by the composite response of 2-grade improvement on subject's self-assessment (SSA) at maximum contraction [Time Frame: At Week 4]) , according to an Ipsen media release
  • 22 Sep 2025 Primary endpoint has been met (Response to treatment as measured by the composite response of 2-grade improvement on ILA at maximum contraction on the forehead lines (FHL) area [ Time Frame: At Week 4 ]) , according to an Ipsen media release
  • 22 Sep 2025 According to an Ipsen media release, data to be presented at upcoming scientific conference in H1 2026 and phase III start-up activities initiated.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top